311 FEASIBILITY OF CATHETER-BASED RENAL DENERVATION AND EFFECTS ON SYMPATHETIC NERVE ACTIVITY AND BLOOD PRESSURE IN PATIENTS WITH END-STAGE RENAL DISEASE

2012 ◽  
Vol 30 ◽  
pp. e91-e92 ◽  
Author(s):  
Markus P Schlaich ◽  
Bradley Bart ◽  
Dagmara Hering ◽  
Felix Mahfoud ◽  
Michael Böhm ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Sympathetic Nerve ◽  
Renal Denervation ◽  
Sympathetic Nerve Activity ◽  
Nerve Activity ◽  
Stage Renal Disease ◽  
End Stage

Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease

2010 ◽  
Vol 28 (9) ◽  
pp. 1920-1927 ◽  
Author(s):  
Martin Hausberg ◽  
Faruk Tokmak ◽  
Hermann Pavenstädt ◽  
Bernhard K Krämer ◽  
Lars Christian Rump
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Sympathetic Nerve ◽  
Sympathetic Nerve Activity ◽  
Nerve Activity ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Differential distribution of muscle and skin sympathetic nerve activity in patients with end-stage renal disease

2008 ◽  
Vol 105 (6) ◽  
pp. 1873-1876 ◽  
Author(s):  
Jeanie Park ◽  
Vito M. Campese ◽  
Niloofar Nobakht ◽  
Holly R. Middlekauff
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Sympathetic Nerve ◽  
Sympathetic Nerve Activity ◽  
Differential Distribution ◽  
Nerve Activity ◽  
Sympathetic Overactivity ◽  
Skin Sympathetic Nerve Activity ◽  
Stage Renal Disease ◽  
End Stage

End-stage renal disease (ESRD) is characterized by resting sympathetic overactivity. Baseline muscle sympathetic nerve activity (MSNA), which is governed by baroreflexes and chemoreflexes, is elevated in ESRD. Whether resting skin sympathetic nerve activity (SSNA), which is independent from baroreflex and chemoreflex control, is also elevated has never been reported in renal failure. The purpose of this study was to determine whether sympathetic overactivity of ESRD is generalized to include the skin distribution. We measured sympathetic nerve activity to both muscle and skin using microneurography in eight ESRD patients and eight controls. MSNA was significantly ( P = 0.025) greater in ESRD (37.3 ± 3.6 bursts/min) when compared with controls (23.1 ± 4.4 bursts/min). However, SSNA was not elevated in ESRD (ESRD vs. controls, 17.6 ± 2.2 vs. 16.1 ± 1.7 bustst/min, P = 0.61). Similar results were obtained when MSNA was quantified as bursts per 100 heartbeats. We report the novel finding that although sympathetic activity directed to muscle is significantly elevated, activity directed to skin is not elevated in ESRD. The differential distribution of sympathetic outflow to the muscle vs. skin in ESRD is similar to the pattern seen in other disease states characterized by sympathetic overactivity such as heart failure and obesity.

scholarly journals Sympathetic Nerve Activity in End-Stage Renal Disease

Circulation ◽  
2002 ◽  
Vol 106 (15) ◽  
pp. 1974-1979 ◽  
Author(s):  
Martin Hausberg ◽  
Markus Kosch ◽  
Patrick Harmelink ◽  
Michael Barenbrock ◽  
Helge Hohage ◽  
...  
Keyword(s):  
Renal Disease ◽  
End Stage Renal Disease ◽  
Sympathetic Nerve ◽  
Sympathetic Nerve Activity ◽  
Nerve Activity ◽  
Stage Renal Disease ◽  
End Stage

EFFECTS OF RENAL DENERVATION ON BLOOD PRESSURE IN PATIENTS WITH END-STAGE RENAL DISEASE

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e49
Author(s):  
C. Ott ◽  
A. Schmid ◽  
T. Ditting ◽  
R. Veelken ◽  
M. Uder ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Renal Denervation ◽  
Stage Renal Disease ◽  
End Stage

scholarly journals Effects of Variability in Blood Pressure, Glucose, and Cholesterol Concentrations, and Body Mass Index on End-Stage Renal Disease in the General Population of Korea

2019 ◽  
Vol 8 (5) ◽  
pp. 755 ◽  
Author(s):  
Mee Kyoung Kim ◽  
Kyungdo Han ◽  
Hun-Sung Kim ◽  
Yong-Moon Park ◽  
Hyuk-Sang Kwon ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Body Mass Index ◽  
General Population ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
High Variability ◽  
Metabolic Parameters ◽  
Metabolic Parameter ◽  
Stage Renal Disease ◽  
End Stage

Aim: Metabolic parameters, such as blood pressure, glucose, lipid levels, and body weight, can interact with each other, and this clustering of metabolic risk factors is related to the progression to end-stage renal disease (ESRD). The effect of variability in metabolic parameters on the risk of ESRD has not been studied previously. Methods: Using nationally representative data from the Korean National Health Insurance System, 8,199,135 participants who had undergone three or more health examinations between 2005 and 2012 were included in this analysis. Intraindividual variability in systolic blood pressure (SBP), fasting blood glucose (FBG), total cholesterol (TC), and body mass index (BMI) was assessed by examining the coefficient of variation, variability independent of the mean, and average real variability. High variability was defined as the highest quartile of variability and low variability was defined as the lower three quartiles of variability. Results: Over a median (5–95%) of 7.1 (6.5–7.5) years of follow-up after the variability assessment period, 13,600 (1.7/1000 person-years) participants developed ESRD. For each metabolic parameter, an incrementally higher risk of ESRD was observed for higher variability quartiles compared with the lowest quartile. The risk of ESRD was 46% higher in the highest quartile of SBP variability, 47% higher in the highest quartile of FBG variability, 56% higher in the highest quartile of BMI variability, and 108% higher in the highest quartile of TC variability. Compared with the group with low variability for all four parameters, the group with high variability for all four parameters had a significantly higher risk for incident ESRD (hazard ratio (HR) 4.12; 95% CI 3.72–4.57). Conclusions: Variability in each metabolic parameter was an independent predictor of the development of ESRD among the general population. There was a composite effect of the variability in additional metabolic parameters on the risk of ESRD.

The Potential Role of Catheter-Based Renal Sympathetic Denervation in Chronic and End-Stage Kidney Disease

2016 ◽  
Vol 21 (4) ◽  
pp. 344-352 ◽  
Author(s):  
Yusuke Sata ◽  
Markus P. Schlaich
Keyword(s):  
Blood Pressure ◽  
Renal Function ◽  
Kidney Disease ◽  
End Stage Renal Disease ◽  
Renal Denervation ◽  
Potential Role ◽  
Stage Renal Disease ◽  
End Stage ◽  
Renal Sympathetic

Sympathetic activation is a hallmark of chronic and end-stage renal disease and adversely affects cardiovascular prognosis. Hypertension is present in the vast majority of these patients and plays a key role in the progressive deterioration of renal function and the high rate of cardiovascular events in this patient cohort. Augmentation of renin release, tubular sodium reabsorption, and renal vascular resistance are direct consequences of efferent renal sympathetic nerve stimulation and the major components of neural regulation of renal function. Renal afferent nerve activity directly influences sympathetic outflow to the kidneys and other highly innervated organs involved in blood pressure control via hypothalamic integration. Renal denervation of the kidney has been shown to reduce blood pressure in many experimental models of hypertension. Targeting the renal nerves directly may therefore be specifically useful in patients with chronic and end-stage renal disease. In this review, we will discuss the potential role of catheter-based renal denervation in patients with impaired kidney function and also reflect on the potential impact on other cardiovascular conditions commonly associated with chronic kidney disease such as heart failure and arrhythmias.

Sign in / Sign up

Export Citation Format

Share Document